– SWEDEN, Stockholm – Aprea AB, a Karolinska Development AB (STO: KDEV) portfolio company, announces that Bernd R. Seizinger has been elected as Executive Chairman and Jonathan Hepple a new member of the board.
Bernd R. Seizinger, M.D., Ph.D., is Chairman of Opsona Therapeutics Ltd. He was formerly Vice President, Oncology Drug Discovery at Bristol-Myers Squibb, Director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital and Associate Professor at Harvard Medical School in Boston, MA, USA, as well as President & CEO of oncology drug discovery and clinical development company GPC Biotech (U.S. and Germany). Dr. Seizinger has authored more than 100 publications and has been the recipient of numerous scientific awards. He has been on the board of a number of private and public biotech and pharma companies in the U.S. and Europe.
Jonathan Hepple PhD., represents Rosetta Capital Ltd where he is one of the founding Partners. Jonathan has over 17 years of investment experience in the life sciences initially at Rothschild Asset Management and then as co-founder of BioScience Managers Ltd. Jonathan currently serves as a Director on the Board of a number of private life science companies including Novimmune, Procertus and Clanotech. He was previously a Director of Covagen AG and Opsona Therapeutics. He received his PhD from Cambridge University for cancer research.
“Jonathan’s experience in the life science industry, as well as his unique network in the international pharmaceutical and financial industry, and Bernd with his extensive senior leadership experience from the pharmaceutical and biotechnology industries will be a great benefit to the company as we move forward.”, says Ulf Björklund, CEO.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.